Cite
Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate
MLA
Lindberg, Mattias F., et al. “Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate.” Journal of Medicinal Chemistry, vol. 66, no. 23, Dec. 2023, pp. 15648–70. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.3c01888.
APA
Lindberg, M. F., Deau, E., Miege, F., Greverie, M., Roche, D., George, N., George, P., Merlet, L., Gavard, J., Brugman, S. J. T., Aret, E., Tinnemans, P., de Gelder, R., Sadownik, J., Verhofstad, E., Sleegers, D., Santangelo, S., Dairou, J., Fernandez-Blanco, A., … Meijer, L. (2023). Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate. Journal of Medicinal Chemistry, 66(23), 15648–15670. https://doi.org/10.1021/acs.jmedchem.3c01888
Chicago
Lindberg, Mattias F., Emmanuel Deau, Frédéric Miege, Marie Greverie, Didier Roche, Nicolas George, Pascal George, et al. 2023. “Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate.” Journal of Medicinal Chemistry 66 (23): 15648–70. doi:10.1021/acs.jmedchem.3c01888.